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Abstract
Background: Cardiopulmonary bypass (CPB) surgery initiates a controlled systemic inflammatory response characterized by
a cytokine storm, monocytosis and transient monocyte activation. However, the responsiveness of monocytes to Toll-like
receptor (TLR)-mediated activation decreases throughout the postoperative course. The purpose of this study was to
identify the major signaling pathway involved in plasma-mediated inhibition of LPS-induced tumor necrosis factor (TNF)-a
production by monocytes.
Methodology/Principal Findings: Pediatric patients that underwent CPB-assisted surgical correction of simple congenital
heart defects were enrolled (n=38). Peripheral blood mononuclear cells (PBMC) and plasma samples were isolated at
consecutive time points. Patient plasma samples were added back to monocytes obtained pre-operatively for ex vivo LPS
stimulations and TNF-a and IL-6 production was measured by flow cytometry. LPS-induced p38 mitogen-activated protein
kinase (MAPK) and nuclear factor (NF)-kB activation by patient plasma was assessed by Western blotting. A cell-permeable
peptide inhibitor was used to block STAT3 signaling. We found that plasma samples obtained 4 h after surgery, regardless
of pre-operative dexamethasone treatment, potently inhibited LPS-induced TNF-a but not IL-6 synthesis by monocytes. This
was not associated with attenuation of p38 MAPK activation or IkB-a degradation. However, abrogation of the IL-10/STAT3
pathway restored LPS-induced TNF-a production in the presence of suppressive patient plasma.
Conclusions/Significance: Our findings suggest that STAT3 signaling plays a crucial role in the downregulation of TNF-a
synthesis by human monocytes in the course of systemic inflammation in vivo. Thus, STAT3 might be a potential molecular
target for pharmacological intervention in clinical syndromes characterized by systemic inflammation.
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Introduction
Cardiopulmonary bypass-assisted surgery initiates a systemic
inflammatory response induced by extrinsic (e.g. anesthesia,
contact activation within the extracorporeal circuit, endotoxemia)
and intrinsic (e.g. tissue damage, endothelial cell activation,
ischemia-reperfusion injury of myocardium) factors [1–3]. Mono-
cytes are important players in systemic inflammation and the main
producers of pro- and anti-inflammatory cytokines upon activation
of innate pattern recognition receptors [4]. Significant changes in
surface biomarkers on circulating monocytes such as HLA-DR
[5,6] and chemokine receptor CX3CR1 [7] have been observed in
critical illness. Moreover, monocytes activated by the extracorpo-
real circuit extravasate to peripheral tissues with upregulation of
adhesion molecule CD11b [8]. During this dysregulation of
inflammatory homeostasis, increased levels of pro-inflammatory
plasma mediators such as TNF-a, IL-6 and IL-8 are joined by
anti-inflammatory cytokines such as IL-10 and TGF-b [9–12].
Importantly, the net effect of these circulating inflammatory
mediators appears to be biased towards inhibition of innate
immune cells, thereby providing timely negative feedback.
However, the molecular and cellular mechanisms responsible for
suppression of the immune system after on-pump cardiac surgery
remain unclear [13].
The anti-inflammatory phase in systemic inflammation is
associated with a reduced TLR responsiveness of monocytes
[14,15]. Monocytes respond to LPS stimulation through the
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TLR4 [16,17], which results in NF-kB activation. Altered
monocyte reactivity to LPS after on-pump cardiac surgery by
plasma mediators may therefore be caused by reduced availability
of TLR ligands (i.e. free LPS), by upregulation of circulating LBP
[18] or lipoproteins [19]. Alternative explanations include
downregulation of TLR4 and the resulting inhibition of down-
stream signaling cascades [20,21], prevention of IkB-a degrada-
tion, the negative regulator of NF-kB [22,23], or finally, the effects
of signaling cascades [e.g. Signal transducer and activator of
transcription (STAT)3] activated by the prototypic anti-inflam-
matory cytokine IL-10 [14].
In the present study, we evaluated these possibilities in order to
identify the molecular mechanism behind the diminished response
of monocytes to LPS stimulation during human systemic
inflammation in vivo. Set against (pre-)clinical sepsis models,
CPB-assisted cardiac surgery allows serial sampling of cells and
plasma from the incitement, expansion, up to the resolution phase
of human systemic inflammation, as previously shown [24]. Only
patients with a favorable outcome were included in order to
provide a controlled system of inflammatory evolution. We tested
the capability of patient plasma isolated at different time points to
inhibit LPS-induced TNF-a and IL-6 synthesis by monocytes.
Subsequently, we tested the requirement of IL-10/STAT3
signaling for the effects of anti-inflammatory plasma on monocytes
ex vivo.
Results
Activation of the innate immune system after on-pump
cardiac surgery
As expected, cardiac surgery led to in vivo activation of the
innate immune system. Mean cell counts increased significantly
24 h after surgery for both the neutrophil (9.7962.74 vs.
3.1061.94?10
9/L, Fig. 1A) and monocyte (1.8760.89 vs.
0.5760.25?10
9/L, Fig. 1B) populations compared to baseline.
Accordingly, the pro-inflammatory CD14+CD16+ monocyte
subpopulation had expanded significantly 24 h after surgery
(0.5160.34 vs. 0.04460.025?10
9/L; Fig. 1C). These events were
paralleled by elevated plasma levels of C-reactive protein 24–48 h
after surgery (Fig. 1D), whereas we observed a transient
lymphopenia 4 h after surgery (Fig. 1E). Analysis of plasma
samples by multiplex immunoassay showed a marked increase of
biomarkers that have been associated with a deleterious course in
human systemic inflammation [25], including IL-6, IL-8, TNF-a,
MIF (all pro-inflammatory) and IL-10 (anti-inflammatory,
Fig. 1F). Thus, on-pump cardiac surgery leads to a temporary,
controlled activation of the innate immune system with both
strong pro- and anti-inflammatory signals.
Inhibition of LPS-induced monocyte TNF-a synthesis by
post-perfusion plasma
Next, we assessed the functional consequences of the dramatic
peri- and postoperative release of inflammatory mediators on
TLR-mediated monocyte activation. To study this, we stimulated
thawed PBMC from patients obtained at various time points with
E. coli LPS for 4 h in standard culture medium. Monocytes were
the major responders to LPS-stimulation in PBMC as determined
by intracellular TNF-a synthesis measured by FACS. However,
we found only a marginal decrease in TNF-a production by
patient monocytes in the course of CPB surgery (Fig. 2A).
Accordingly, TLR4 expression levels on monocytes did not
significantly change during the study period (TLR4 MFI Pre-op,
End-CPB, 24 h and 48 h after surgery was 2.461.3, 2.361.1,
2.661.5 and 2.361.6, respectively). We then stimulated fresh
whole blood samples obtained from patients at consecutive time-
points with LPS ex vivo. Importantly, we now found a marked
decrease of monocyte TNF-a production, which was maximal 4 h
after surgery compared to baseline (Fig. 2B). These findings
suggested that, although the intrinsic capacity of monocytes to
respond to LPS did not change, plasma factors released in the
course of on-pump cardiac surgery might influence their capacity
to synthesize TNF-a.
To test this, we next stimulated thawed patient PBMC isolated
before surgery with LPS in the presence of autologous plasma
obtained at different time points or with plasma from healthy
donors (control). Importantly, by using the same monocyte
population for all experimental conditions (see experimental setup
in Fig. 2C), we could specifically address the regulatory role of
plasma components released in the course of human systemic
inflammation on monocytes. As shown in Fig. 2D, we found
significantly reduced TNF-a production in the presence of plasma
obtained before surgery, at the end of CPB and maximal
suppression mediated by 4 h post-surgery plasma (all P,0.001
vs. control). Importantly, the number of TNF-a positive LPS-
stimulated monocytes in the presence of 4 h post-surgery plasma
was significantly lower compared to pre-operative and 24 h post-
surgery plasma (P,0.05 and P,0.001, respectively). Surprisingly,
we did not observe a similar inhibitory effect of 4 h post-surgery
plasma on IL-6 synthesis (Fig. 2E). Analysis of the mean
fluorescence intensities of TNF-a and IL-6 in LPS-stimulated
monocytes to compare their respective expression levels in the
different plasma milieus reproduced the same results (Fig. 2H).
Thus, plasma mediators released in the circulation 4 h after open
heart surgery strongly suppressed LPS-induced TNF-a but not IL-
6 synthesis by monocytes.
Since all patients analyzed had received dexamethasone pre-
operatively, we had to exclude that this anti-inflammatory agent
influenced our ex vivo monocyte assays. We therefore first
measured dexamethasone levels in consecutive patient plasma
samples and found that these were maximal in pre-operative
samples, but already significantly reduced 4 h post-surgery
(Fig. 2F). To further exclude the potential influence of steroids
on the effects of 4 h post-perfusion plasma, we enrolled a control
group that did not receive dexamethasone before surgery. The
clinical characteristics of these patients were comparable to the
previously analyzed cohort of patients (Table 1). We repeated the
ex vivo plasma assays as before and analyzed LPS-induced TNF-a
and IL-6 production by monocytes. Again, we found a significant
effect of 4 h post-perfusion plasma samples on TNF-a production
by monocytes (Fig. 2G). However, the inhibitory effects of Pre-op
and End-CPB plasma samples on TNF-a synthesis were not found
in the absence of dexamethasone. Moreover, there was no
suppression of IL-6 in any of the steroid-free conditions tested
(Fig. 2G). Representative results of a patient from the No-
dexamethasone group are shown in Fig. 2I. We inferred from
these data that 4 h post-perfusion plasma has a unique inhibitory
effect on LPS-induced TNF-a but not IL-6 synthesis by
monocytes.
Normal activation of p38 MAPK and NF-kB in the
presence of post-perfusion plasma
Next, we sought to elucidate the molecular mechanisms that
could account for the suppression of 4 h post-surgery plasma on
LPS-induced TNF-a production by monocytes. To test whether
this could be explained by either sequestration of LPS in post-
surgery plasma or reduced TLR4 expression on monocytes, we
evaluated for differences in activation of signaling pathways
STAT3 Regulates Human Systemic Inflammation
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35070downstream of TLR4. To this end, we compared the effects of 4 h
vs. 24 h post-perfusion plasma samples from the same patient,
since the latter did not significantly reduce LPS-induced TNF-a
synthesis (see Fig. 2G). All three MAPK pathways i.e. p38, JNK/
SAPK and ERK are activated by LPS in monocytes [26]. Since we
found that the p38 MAPK pathway was most potently activated
by LPS, we assessed the activation of p38 MAPK in purified
monocytes isolated from healthy donors stimulated with LPS in
the presence of patient plasma obtained 4 h or 24 h (control) post-
surgery. As shown in Fig. 3A, there was no attenuation of p38
activation in monocytes after LPS stimulation in the presence of
4 h post-surgery plasma compared to control plasma. In contrast,
densitometric analysis of Western blots from 4 different patients
showed even slightly increased p38 MAPK phosphorylation in the
presence of suppressive 4 h post-surgery plasma (Fig. 3B). IkB-a
negatively regulates NF-kB by sequestering this transcription
factor in the cytosol [27]. LPS-mediated phosphorylation of IkB-a
induces its ubiquitination and degradation, resulting in the release
of NF-kB. Evaluation of IkB-a phosphorylation after LPS
stimulation showed similar kinetics in the presence of either 4 h
or 24 h post-surgery plasma (Fig. 3A,C). Thus, we inferred from
these results that suppression of LPS-induced TNF-a production
by monocytes mediated by 4 h post-surgery plasma is not due to
reduced TLR4 and subsequent p38 MAPK and NF-kB activation.
A regulatory role of STAT3 signaling induced by
inhibitory post-perfusion plasma
We next set out to assess the role of immunomodulatory
cytokines in our system. As shown above, we identified high levels
of the anti-inflammatory cytokine IL-10 in these plasma samples
(Fig. 1F). As monocytes/macrophages have been shown to be
both the main producers [28] and target cells of IL-10 [29], we
first evaluated the effect of IL-10 neutralization. Plasma samples
obtained 4 h post-surgery were pre-treated with anti-hIL-10 mAb
(10 or 100 mg/mL), or the appropriate isotype control (IgG2a,
100 mg/mL), before adding these samples back to PBMC in the
presence of LPS. As shown in Fig. 4A, we found that
neutralization of IL-10 partially reversed the inhibitory effects of
4 h post-surgery plasma on TNF-a synthesis by monocytes.
IL-10 activates the JAK1/STAT3 pathway by signaling
through the IL-10 receptor (IL-10R) in mononuclear cells
[30,31]. This IL-10R/STAT3 signaling axis results in the
upregulation of various anti-inflammatory proteins that can inhibit
pro-inflammatory cytokine synthesis [32,33]. Indeed, we found
activation of STAT3 in monocytes by incubation with plasma
isolated 4 h but not 24 h post-perfusion regardless of the presence
of LPS (representative example in Fig. 4B). Therefore, we next
assessed the functional role of STAT3 signaling in monocytes with
regard to the suppressive effects of post-perfusion plasma on
cytokine production. We pre-treated patient PBMC with a cell-
permeable STAT3 inhibitor peptide (phosphorylated peptide, pY-
Figure 1. Inflammatory events induced by CPB surgery. Increased mean neutrophil (A) and monocyte (B) counts after on-pump cardiac
surgery (n=21 and n=24, respectively). C. Increased numbers of circulating CD14+CD16+ monocytes after CPB surgery (n=14). D. Increased mean
C-reactive protein (CRP) levels in patient blood samples post-surgery (n=22). E. Lymphopenia was observed 4 h post-surgery (n=27). Box-and-
whiskers plots. *P,0.01, **P,0.001 vs. pre-op (ANOVA). F. Cyto- and chemokine color profiles of plasma samples (n=12) obtained at indicated time
points, represented as % change compared to baseline. MIF: Macrophage migration inhibitory factor.
doi:10.1371/journal.pone.0035070.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35070Figure 2. Post-perfusion plasma suppresses LPS-induced TNF-a production by monocytes. A. Percentage of TNF-a producing cells in the
monocyte population after ex vivo LPS stimulation (100 ng/mL) of patient PBMC isolated at various time points (n=4). B. Reduced TNF-a synthesis by
monocytes after LPS (10 ng/mL) stimulation in whole blood assays with patient samples obtained at the indicated time points (n=5). C. Experimental
setup for experiments shown in D,E,G-I. In short, patient PBMC obtained before surgery (Pre-op) were mixed with control (pooled AB plasma from
healthy donors) or autologous patient plasma samples obtained at indicated time points, followed by LPS (100 ng/mL) stimulation for 4 h. Monocyte
populations (CD14/SSC gate) were then analyzed for intracellular TNF-a and IL-6 synthesis. D. Significantly reduced production of TNF-a by
monocytes after LPS stimulation in the presence of plasma samples from different sources (n=13). Shown are percentages of TNF-a producing
monocytes relative to control (100%). *P,0.05, **P,0.001 vs. control (ANOVA). E. Percentages of IL-6 producing monocytes as in D. **P,0.001 vs.
control (ANOVA). F. Dexamethasone levels in patient plasma samples as measured by radio-immunoassay (n=9). Median 6 interquartile range.
*P,0.05 vs. pre-op (ANOVA). G. Production of TNF-a and IL-6 by monocytes after LPS stimulation in the presence of dexamethasone-free plasma
samples (n=4). *P,0.05 vs. control (ANOVA). H. Mean fluorescence intensities (MFI) of TNF-a and IL-6 in monocytes after LPS stimulation in different
plasma milieus (n=7). *P,0.05, **P,0.001 vs. control (ANOVA). I. Representative flow cytometry results (contour plots) of the LPS-induced TNF-a
production by monocytes in the presence of control or patient plasma (Pre-op, End-CPB, 4 h or 24 h post-perfusion plasma from a No-
dexamethasone patient). Isotype control: mouse IgG1. Data represented as mean 6 SEM, unless otherwise indicated.
doi:10.1371/journal.pone.0035070.g002
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prevents nuclear translocation of STAT3 dimers [34]. After pre-
treatment with pY-STAT3i or non-phosphorylated control
peptide (STAT3i), the cells were again stimulated with LPS in
the presence of 4 h post-perfusion plasma and the results were
compared to those obtained with 24 h post-surgery (control)
plasma. We found that STAT3 inhibition restored TNF-a
production in the presence of suppressive patient plasma
(Fig. 4C, left panel), but did not affect IL-6 synthesis
(Fig. 4C, right panel). STAT3 inhibition also restored levels
of TNF-a, but not IL-6, in supernatants of LPS-stimulated
mononuclear cells incubated in the presence of 4 h post-perfusion
plasma (Fig. 4D). In all experiments, pre-treatment with control
peptide had no effect on cytokine production (Fig. 4C,D). Taken
together, our findings suggest that STAT3 mediates the suppres-
sive effects of plasma mediators (released shortly after CPB
surgery) on TNF-a, but not IL-6, synthesis by monocytes.
Discussion
A suppressed immune system after cardiac surgery is extensively
described in both adult and pediatric patients and is associated
with an enhanced risk of nosocomial infections and prolonged
hospital stay [35,36]. Previous studies identified both phenotypic
cellular changes, such as HLA-DR expressed on monocytes [5]
and soluble factors including IL-10 [14,37], to be associated with
clinical outcome. Our data showed a transient suppression of
monocyte function in the circulation after open heart surgery,
which was mainly caused by plasma components (Fig. 2). Previous
dissections of signaling cascades responsible for suppression of the
innate immune system in systemic inflammation have lead to the
concept of ‘endotoxin tolerance’, particularly in human endotox-
emia and sepsis. These conditions are associated with the
upregulation of intracellular negative regulators of TLR4
signaling, including IL-1R-associated kinase (IRAK)-M [38],
MyD88s and single immunoglobulin interleukin-1 receptor-related
molecule (SIGIRR) [39]. However, we found that major signaling
pathways downstream of TLR4 (i.e. p38 MAPK and NF-kB
activation) were unimpaired in the presence of suppressive patient
plasma (Fig. 3). This suggests that the suppression of LPS-induced
TNF-a production by monocytes in our model was not explained
by endotoxin tolerance.
Transcriptional activity of STAT3 in macrophages and
neutrophils has been shown to be essential for the orchestration
of anti-inflammatory responses in experimental models of systemic
inflammation [40,41]. Currently, there is limited information on
the role of STAT3 in anti-inflammatory feedback on innate
immune cells in human (sterile) systemic inflammation [42,43].
Here we demonstrate a crucial role for STAT3 in the suppression
of TNF-a synthesis by monocytes in the course of systemic
inflammation associated with on-pump cardiac surgery in a well
described pediatric patient population (Fig. 4). JAK1/STAT3
signaling has been studied broadly in primary mononuclear cells in
vitro and both JAK1 and STAT3 are required for IL-10 mediated
inhibition of LPS-induced TNF-a production [44]. On-pump
cardiac surgery has been shown to induce the release of cytokines
(IL-6, IL-10) associated with JAK1/STAT3 signaling [10,14,45],
as confirmed in the present study (Fig. 1F). Neutralization of IL-
10 in suppressive plasma samples partially reversed its inhibitory
effects on LPS-induced TNF-a synthesis (Fig. 4A), which
suggested involvement of downstream JAK1/STAT3 signaling.
We subsequently found that pre-treatment of monocytes with a
specific STAT3 peptide inhibitor ex vivo indeed restored TNF-a
Table 1. Patient characteristics.
Dexamethasone No-Dexamethasone P-value
Age (mo) 12634 766 0.14
Male / female 19/15 1/3
VSD 16 3
ASD 12 1
AVSD 2
Aortic valvuloplasty 2
Extracardiac conduit 1
CoA 1
Duration of CPB (min) 52628 49629 0.82
Duration of ACC (min) 32620 42617 0.26
PICU stay (days) 261.2 160 0.17
Age, CPB, ACC and PICU durations represented as median 6 SD. ACC: aortic
crossclamping, ASD: atrial septum defect, AVSD: atrioventricular septum defect,
CoA: Coarctation aorta, CPB: cardiopulmonary bypass, Extracardiac conduit
change due to stenosis after Fontan procedure, PICU: pediatric intensive care
unit, VSD: ventricular septum defect. No significant differences were found
between both patient groups (Mann-Whitney test).
doi:10.1371/journal.pone.0035070.t001
Figure 3. Post-perfusion plasma does not interfere with p38 MAPK or NF-kB activation. Representative examples (A) and densitometric
analyses (B–C) of LPS-induced p38 MAPK and IkB-a phosphorylation in monocytes in the presence of 24 h (control) or 4 h post-surgery plasma.
Tubulin: loading control. Mean 6 SEM (n=4). *P,0.05 vs. 0 min (ANOVA).
doi:10.1371/journal.pone.0035070.g003
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critical signaling hub used by both pro- and anti-inflammatory
signals mediated by IL-6 and IL-10, respectively [46,47]. These
apparent paradoxical inputs are differentially regulated by
suppressor of cytokine signaling (SOCS)3 [32]. While the IL-6
receptor is susceptible to feedback inhibition by SOCS3, the IL-
10R is not. The IL-10R-induced STAT3 pathway induces a
transcriptional program of anti-inflammatory gene products
resulting in the repression of pro-inflammatory transcripts
[48,49]. Surprisingly, STAT3 inhibition in our study failed to
reverse the suppression of IL-6 production by monocytes in the
presence of post-perfusion plasma, in contrast to TNF-a
(Fig. 4C,D). This unexpected finding warrants further dissection
of the exact molecular mechanisms used by STAT3 to selectively
regulate TNF-a synthesis in human monocytes. Besides an
important regulator of inflammation, STAT3 plays a potential
role in cytoprotection and regeneration. With regard to cardiac
surgery, STAT3 contributes to cardioprotective mechanisms in
ischemia-reperfusion injury [50,51], with a major role for IL-6 in
the induction of this pathway [52]. Thus, our results add another
feature to the multifaceted properties of STAT3 signaling in
different cell types to promote tissue homeostasis after cardiac
surgery.
Pharmacological agents administered during and after the
surgical and anesthesiological procedures could have affected our
ex vivo plasma assays. In particular, the pre-operative administra-
tion of dexamethasone (standard practice for this type of surgery in
our hospital and most other institutions [53]) may be of influence,
as corticosteroids are known for their potent anti-inflammatory
effects on innate immune cells. However, we found that the
circulating levels of dexamethasone were already significantly
reduced 4 h after surgery (Fig. 2F). More importantly, we
repeated the key experiments with plasma samples obtained from
patients that did not receive steroids before the procedure (clinical
characteristics in Table 1). Steroid-free plasma isolated shortly
(4 h) after open heart surgery was still able to suppress LPS-
induced TNF-a production by monocytes (Fig. 2G). These results
also suggest that the suppressive plasma components were not
Figure 4. STAT3 signaling is required for the suppressive effects of post-perfusion plasma on TNF-a production. A. Pre-treatment of
4 h post-surgery plasma samples with anti-IL-10 partially restored TNF-a production by patient monocytes in response to LPS (n=10). Control:
plasma from healthy donors. B. Activation of STAT3 in monocytes by incubation with suppressive (4 h post-perfusion) but not control (24 h post-
perfusion) plasma. Cells were incubated in the absence or presence of LPS to match the experimental setup as in Fig. 2. C. Pre-treatment of patient
PBMC with active STAT3 inhibitor (pY-STAT3i) but not control peptide (STAT3i) before LPS stimulation in the presence of post-surgery plasma
restored TNF-a synthesis (left panel), in contrast to IL-6 (right panel). Shown are percentages of TNF-a and IL-6 producing monocytes normalized to
control (24 h post-surgery) plasma (n=8). D. TNF-a and IL-6 levels measured in supernatants of LPS-stimulated mononuclear cells after pre-treatment
with STAT3 inhibitor or control peptide, in the presence of 4 h post-surgery plasma (n=8). Cytokine levels were normalized to LPS stimulation in
control plasma from healthy donors due to interassay variability. All results are depicted as mean 6 SEM. *P,0.05 vs. control condition (ANOVA), ns:
not significant.
doi:10.1371/journal.pone.0035070.g004
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with plasma with and without dexamethasone (compare Fig. 2D,
E and Fig. 2G, respectively), we inferred that only the suppressive
effect of 4 h post-perfusion plasma on TNF-a synthesis was likely
caused by endogenous plasma factors. No effect on IL-6 synthesis
by monocytes was found with steroid-free plasma which is
consistent with our observations that abrogation of IL10/STAT3
signaling did not affect IL-6 production in monocytes (Fig. 4).
Please note that due to limited availability of these steroid-free
samples we could not perform additional experiments with IL-10
neutralizing antibodies and STAT3 inhibitor peptide.
We demonstrated a non-redundant role for STAT3 in
mediating negative feedback on LPS-induced monocyte TNF-a
(but not IL-6) production after on-pump cardiac surgery. This
supports the concept of specific monocyte reprogramming in the
course of human systemic inflammation, rather than general
immune suppression. Our findings suggest that functional
modulation of STAT3 activity offers a potential target for
molecular intervention in suppressed states of the innate immune
system in human disease.
Materials and Methods
Ethics Statement
Written informed consent was obtained from the parents of
children participating in the study. A medical ethics committee
(Medische Ethische Toetsings Commissie UMC Utrecht) ap-
proved this study (METC 03/049-K, 04/144-K UMC Utrecht,
The Netherlands) and all procedures were in accordance with
institutional guidelines.
Study population, surgical and anesthesiological
procedures
Children admitted to our hospital for surgical repair of relatively
simple congenital heart defects with an expected rapid recovery
were enrolled. For this purpose, we only included patients who
underwent a surgical procedure from RACHS-1 (Risk Adjustment
for Congenital Heart Surgery) score of 2 or less [54]. Patients that
had signs of infection or a documented immunodeficiency were
excluded. A total of 38 children were enrolled in the study and all
experienced an uneventful peri- and postoperative clinical course.
Detailed clinical characteristics are depicted in Table 1. The
surgical, anesthesiological and cardiopulmonary bypass proce-
dures have been published previously [24]. Briefly, general
anesthesia was always implemented using a standard technique
involving sufentanil, midazolam, pancuronium, dopamine and
milrinone. All patients received 48 hours perioperative antibiotic
prophylaxis with Cefazolin. Patients receiving dexamethasone
were given a single dose of dexamethasone (1 mg/kg) after
induction of anesthesia. Four patients received no steroids before
the procedure. Non-pulsatile cardiopulmonary bypass was used,
the standard pump flow rate was 2.8 liter/m
2/min. Combined
alpha and pH stat management of acid-base status was used
during cardiopulmonary bypass. The cardioplegia procedure was
standardized using St. Thomas’ solution. After weaning from
cardiopulmonary bypass all patients remained intubated and
ventilated and were admitted to the pediatric intensive care for
further management. At the pediatric intensive care patients were
treated with milrinone, midazolam and morphine for maximally
24 hours. All patients were treated by the same surgical and
anesthetic team.
Blood sampling and cell isolation
Blood samples were obtained at the following time points:
immediately after insertion of a central venous catheter during
anesthetic induction (Pre-op), at the end of cardiopulmonary
bypass (End-CPB), 4 h, 24 h and 48 h after surgery. At these time
points, total leucocyte, neutrophil, monocyte, lymphocyte counts
and C-reactive protein (CRP) levels were determined. Fresh
heparinized blood samples were used for full blood assays. For all
other purposes, plasma samples were prepared by centrifugation
and stored at 280uC, whereas PBMC were separated by density
gradient centrifugation over Ficoll-Hypaque (Amersham Pharma-
cia Biotech) and stored in liquid nitrogen, as previously described
[55]. In some assays, pooled human AB plasma from healthy
volunteers (Sanquin Blood Bank, Utrecht, The Netherlands) was
used as control plasma.
Antibodies
Fluorescently labeled or unconjugated monoclonal antibodies
(mAb) directed against human CD14 (murine, clone MOP9,
StemCell Technologies), mouse anti-FccRIII/CD16 (3G8, BD
Biosciences), mouse anti-CD284/TLR4 (HTA125, eBioscience),
mouse anti-TNF-a (Mab11, eBioscience) and rat anti-IL-6 (MQ2-
6A3, BD) were used for flow cytometry. MAbs directed against
hIL-10 (JES3-19F1, rat IgG2a, BD) and rat IgG2a isotype (BD)
were used for neutralization experiments. Antibodies directed
against p-p38, p38, p-IkB-alpha and p-STAT3 (Cell Signaling),
IkB-alpha and STAT3 (Santa Cruz) and Tubulin (Sigma) were
used for Western blotting.
Cellular assays
Whole blood stimulation assays were performed in RPMI-1640
at 1:5 dilution. Cells were incubated with or without LPS
(Escherichia coli O127:B8E, L4517, Sigma) at 10 ng/mL in a 96-
well plate (Costar) for 4 h at 37uC, 5% CO2 with 100% relative
humidity. Cells were then washed and stained for surface markers
followed by lysis of red blood cells (BD Lysing Solution) and
intracellular cytokine staining. For ex vivo LPS stimulation assays,
PBMC from various time points were plated in a 96-well plate at
2610
6 cells/mL in RPMI-1640 supplemented with 2 mmol/L
glutamine, 100 U/mL penicillin/streptomycin (Gibco BRL,
Invitrogen) and 10% (v/v) heat-inactivated human AB serum.
LPS was added (100 ng/mL LPS) for 4 h, followed by intracellular
cytokine staining. For plasma assays, patient PBMC isolated
before surgery were adjusted to 2610
6 cells/mL in supplemented
RPMI-1640 (no serum). Pooled human AB plasma (control) and
autologous patient plasma samples obtained at serial time-points
were thawed and spun (300 g, 10 min) and the supernatants were
filtered (50 mm). Plasma samples mixed with LPS (100 ng/mL end
concentration) were added to equal volumes of cell suspensions
(50% v/v) and incubated for 4 h at 37uC, followed by intracellular
cytokine staining. For IL-10 neutralization assays, patient plasma
samples were pre-incubated with anti-hIL-10 mAb (10–100 mg/
mL) or IgG2a isotype (100 mg/mL) for 1 h at 4uC on a shaker. For
STAT3 inhibition assays, PBMC obtained before surgery were
pre-treated with 0.02 or 0.1 mM cell-permeable STAT3 Inhibitor
Peptide (PpYLKTK-mts, Calbiochem) or 0.1 mM inactive control
peptide (Ac-PpYLKTK-OH) for 1 h at 37uC in culture medium
with 10% AB plasma. PBMC were then washed and mixed with
plasma samples (4 h or 24 h post-surgery) and LPS (100 ng/mL)
for a 4 h incubation period followed by intracellular cytokine
staining.
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Golgistop (2 mM, BD) was added during ex vivo incubations with
LPS. Cells were then washed, blocked with normal mouse serum
followed by extracellular staining, fixation in Cytofix/Cytoperm
and washing in Perm/Wash solution (Cytofix/perm kit, BD).
Finally, cells were incubated with mAbs for intracellular cytokine
staining, as published [24].
Multiplex immunoassay
Multiplex immunoassay with the Bio-Plex suspension array
system (Bio-Rad Laboratories) was used to measure levels of TNF-
a, IL-6, IL-8, IL-10 and MIF in patient plasma samples and
culture supernatants, as previously described [56].
Dexamethasone measurements
Dexamethasone in serum was measured after diethylether
extraction using an in house competitive radio-immunoassay
(RIA) employing a polyclonal anti-dexamethasone-antibody (IgG
dex1 lot 1301; IgG Corporation). [1,2,4,6,7-3H]-dexamethasone
(TRK645, Amersham) was used as a tracer following chromato-
graphic verification of its purity. The lower limit of detection was
20 pmol/L and intra-assay variation was ,7%. All samples were
included in one assay.
Western blot analysis
Purified monocytes from healthy donors were serum starved for
at least 2 h, washed and resuspended in supplemented RPMI-
1640. A total of 5610
5 cells per condition were stimulated in the
absence or presence of LPS (100 ng/mL) for 0, 5, 15 or 240 min
at 37uC in the presence of 50% (v/v) patient plasma. After in vitro
stimulation, cells were washed with cold PBS and lysed in reducing
Laemmli sample buffer. Proteins were separated with SDS-PAGE,
transferred to PVDF membranes, blocked with 5% BSA, followed
by immunoprobing overnight at 4uC. Proteins were detected with
HRP-conjugated secondary antibodies (Dako) and developed with
Hyperfilm ECL (GE Healthcare). Densitometric analysis was
performed with ImageQuant densitometric software (Molecular
Dynamics).
Statistical analysis
Basic descriptive statistics were used to describe the patient
population. Multiple data sets were analyzed by one-way
ANOVA, as indicated. Significance was accepted at *P,0.05
and **P,0.001.
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